For the palliative treatment of metastatic gastric cancer, a doublet containing oxaliplatin and fluoropyrimidines could be considered as an option. Results from a prospective randomized trial showed the non-inferiority of oxaliplatin, as compared to cisplatin, in the treatment of advanced gastric cancer, while decreasing toxicity. Of interest, a subgroup analysis from a phase III randomized trial reported significantly better results for elderly patients treated with oxaliplatin as compared to cisplatin. In this trial, patients with advanced gastric cancer were randomized to receive a 5-FU-based regimen with cisplatin (FLP regimen) or oxaliplatin (FLO regimen). The primary endpoint of the study, PFS, was unmet; however, in the subgroup of patients older than 65 years, the FLO regimen achieved improved efficacy in terms of response rate, PFS, and overall survival (OS) as compared with the FLP regimen.